{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:16:54Z","timestamp":1790842614359,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00415-018-8768-0","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T08:44:09Z","timestamp":1517474649000},"page":"1497-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Intranasal insulin in Alzheimer\u2019s dementia or mild cognitive impairment: a systematic review"],"prefix":"10.1007","volume":"265","author":[{"given":"Konstantinos Ioannis","family":"Avgerinos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios","family":"Kalaitzidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Malli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kalaitzoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos Gr.","family":"Myserlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios-Arsenios","family":"Lioutas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"8768_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.pbr.2017.05.003","volume":"233","author":"L Keuck","year":"2017","unstructured":"Keuck L (2017) Slicing the cortex to study mental illness: alois Alzheimer\u2019s pictures of equivalence. Prog Brain Res 233:25\u201351","journal-title":"Prog Brain Res"},{"issue":"Suppl 1","key":"8768_CR2","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1017\/cjn.2016.36","volume":"43","author":"KM Fiest","year":"2016","unstructured":"Fiest KM, Roberts JI, Maxwell CJ, Hogan DB, Smith EE, Frolkis A et al (2016) The prevalence and incidence of dementia due to Alzheimer\u2019s disease: a systematic review and meta-analysis. Can J Neurol Sci Le journal canadien des sciences neurologiques 43(Suppl 1):S51\u2013S82","journal-title":"Can J Neurol Sci Le journal canadien des sciences neurologiques"},{"issue":"12","key":"8768_CR3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1017\/S1041610217001211","volume":"29","author":"J Olazaran","year":"2017","unstructured":"Olazaran J, Aguera-Ortiz L, Argimon JM, Reed C, Ciudad A, Andrade P et al (2017) Costs and quality of life in community-dwelling patients with Alzheimer\u2019s disease in Spain: results from the GERAS II observational study. Int Psychogeriatr 29(12):2081\u20132093","journal-title":"Int Psychogeriatr"},{"issue":"4","key":"8768_CR4","first-page":"Cd001191","volume":"10","author":"JS Birks","year":"2015","unstructured":"Birks JS, Grimley EJ (2015) Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev 10(4):Cd001191","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"8768_CR5","first-page":"1633","volume":"36","author":"J Jiang","year":"2015","unstructured":"Jiang J, Jiang H (2015) Efficacy and adverse effects of memantine treatment for Alzheimer\u2019s disease from randomized controlled trials. Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol 36(9):1633\u20131641","journal-title":"Neurol Sci Off J Italian Neurol Soc Italian Soc Clin Neurophysiol"},{"issue":"2","key":"8768_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JAD-150346","volume":"48","author":"X Liao","year":"2015","unstructured":"Liao X, Li G, Wang A, Liu T, Feng S, Guo Z et al (2015) Repetitive transcranial magnetic stimulation as an alternative therapy for cognitive impairment in Alzheimer\u2019s disease: a meta-analysis. JAD 48(2):463\u2013472","journal-title":"JAD"},{"issue":"3","key":"8768_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1142\/S0192415X14500335","volume":"42","author":"M Yang","year":"2014","unstructured":"Yang M, Xu DD, Zhang Y, Liu X, Hoeven R, Cho WC (2014) A systematic review on natural medicines for the prevention and treatment of Alzheimer\u2019s disease with meta-analyses of intervention effect of ginkgo. Am J Chin Med 42(3):505\u2013521","journal-title":"Am J Chin Med"},{"key":"8768_CR8","doi-asserted-by":"crossref","unstructured":"Tsolaki MN, Koutsouraki ES, Katsipis GK, Myserlis P Gr., Chatzithoma MA, Pantazaki AA (2017) Alternative anti-infective\/anti-inflammatory therapeutic options for fighting Alzheimer\u2019s disease. In: Frontiers in anti-infective drug discovery, chap 1, vol 6. Bentham Science Publishers, pp 1\u2013153","DOI":"10.2174\/9781681084794117060003"},{"issue":"12","key":"8768_CR9","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","volume":"48","author":"T Cukierman","year":"2005","unstructured":"Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes\u2013systematic overview of prospective observational studies. Diabetologia 48(12):2460\u20132469","journal-title":"Diabetologia"},{"issue":"1","key":"8768_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(05)70284-2","volume":"5","author":"GJ Biessels","year":"2006","unstructured":"Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5(1):64\u201374","journal-title":"Lancet Neurol"},{"issue":"8","key":"8768_CR11","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1084\/jem.20160493","volume":"213","author":"M Stanley","year":"2016","unstructured":"Stanley M, Macauley SL, Holtzman DM (2016) Changes in insulin and insulin signaling in Alzheimer\u2019s disease: cause or consequence? J Exp Med 213(8):1375\u20131385","journal-title":"J Exp Med"},{"issue":"5","key":"8768_CR12","first-page":"482","volume":"1792","author":"WQ Zhao","year":"2009","unstructured":"Zhao WQ, Townsend M (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer\u2019s disease. Biochem Biophys Acta 1792(5):482\u2013496","journal-title":"Biochem Biophys Acta"},{"issue":"6","key":"8768_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/193229680800200619","volume":"2","author":"SM Monte de la","year":"2008","unstructured":"de la Monte SM, Wands JR (2008) Alzheimer\u2019s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2(6):1101\u20131113","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"8768_CR14","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1073\/pnas.0809158106","volume":"106","author":"FG Felice De","year":"2009","unstructured":"De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP et al (2009) Protection of synapses against Alzheimer\u2019s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 106(6):1971\u20131976","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"8768_CR15","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1523\/JNEUROSCI.21-08-02561.2001","volume":"21","author":"L Gasparini","year":"2001","unstructured":"Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P et al (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21(8):2561\u20132570","journal-title":"J Neurosci"},{"issue":"12","key":"8768_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/archpsyc.56.12.1135","volume":"56","author":"S Craft","year":"1999","unstructured":"Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD et al (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56(12):1135\u20131140","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"8768_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0197-4580(95)02002-0","volume":"17","author":"S Craft","year":"1996","unstructured":"Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y et al (1996) Memory improvement following induced hyperinsulinemia in Alzheimer\u2019s disease. Neurobiol Aging 17(1):123\u2013130","journal-title":"Neurobiol Aging"},{"issue":"Suppl 3","key":"8768_CR18","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9","author":"LR Hanson","year":"2008","unstructured":"Hanson LR, Frey WH 2nd (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9(Suppl 3):S5","journal-title":"BMC Neurosci"},{"issue":"7","key":"8768_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","volume":"27","author":"J Freiherr","year":"2013","unstructured":"Freiherr J, Hallschmid M, Frey WH 2nd, Brunner YF, Chapman CD, Holscher C et al (2013) Intranasal insulin as a treatment for Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs 27(7):505\u2013514","journal-title":"CNS Drugs"},{"issue":"4","key":"8768_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12975-015-0409-7","volume":"6","author":"VA Lioutas","year":"2015","unstructured":"Lioutas VA, Alfaro-Martinez F, Bedoya F, Chung CC, Pimentel DA, Novak V (2015) Intranasal insulin and insulin-like growth factor 1 as neuroprotectants in acute ischemic stroke. Transl Stroke Res 6(4):264\u2013275","journal-title":"Transl Stroke Res"},{"issue":"1 Suppl","key":"8768_CR21","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jalz.2013.12.006","volume":"10","author":"C Holscher","year":"2014","unstructured":"Holscher C (2014) First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer\u2019s disease. Alzheimer\u2019s Dementi 10(1 Suppl):S33\u2013S37","journal-title":"Alzheimer\u2019s Dementi"},{"issue":"11","key":"8768_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1358\/dot.2006.42.11.1007675","volume":"42","author":"MA Reger","year":"2006","unstructured":"Reger MA, Craft S (2006) Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin. Drugs Today (Barcelona, Spain: 1998) 42(11):729\u2013739","journal-title":"Drugs Today (Barcelona, Spain: 1998)"},{"issue":"12","key":"8768_CR23","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/archneur.58.12.1985","volume":"58","author":"RC Petersen","year":"2001","unstructured":"Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV et al (2001) Current concepts in mild cognitive impairment. Arch Neurol 58(12):1985\u20131992","journal-title":"Arch Neurol"},{"key":"8768_CR24","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 339:b2535","journal-title":"BMJ (Clinical research ed)."},{"key":"8768_CR25","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 343:d5928","journal-title":"BMJ (Clinical research ed)."},{"key":"8768_CR26","doi-asserted-by":"crossref","unstructured":"Claxton A, Wilkinson C, Baker L, Watson G, Bonner LM, Trittschuh E et al (2012) Intranasal insulin treatment response in Alzheimer\u2019s disease influenced by glucose-stimulated insulin secretion. Alzheimer\u2019s Dementia 8(4 suppl. 1):[P582 p.]. http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clcentral\/articles\/247\/CN-01031247\/frame.html . Accessed 25 May 2017","DOI":"10.1016\/j.jalz.2012.05.1583"},{"key":"8768_CR27","doi-asserted-by":"crossref","unstructured":"Craft S, Claxton A, Hanson A, Cholerton B, Neth B, Trittschuh E et al (2014) Therapeutic effects of intranasal insulin and insulin analogues on cognition and MRI measures in mild cognitive impairment and Alzheimer\u2019s disease. Alzheimer\u2019s Dementia 10:[P126 p.]. http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clcentral\/articles\/790\/CN-01056790\/frame.html . Accessed 25 May 2017","DOI":"10.1016\/j.jalz.2014.04.050"},{"key":"8768_CR28","unstructured":"Rosenbloom M, Barclay T, Pyle M, Owens B, Anderson C, Frey W et al (2013) The effect of intranasal rapid acting insulin on ApoE-epsilon4 carriers with mild-to-moderate Alzheimer\u2019s disease. Alzheimer\u2019s Dementia 9(4 suppl. 1):[P888 p.]. http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clcentral\/articles\/845\/CN-01060845\/frame.html . Accessed 25 May 2017"},{"key":"8768_CR29","unstructured":"Main (2007) Intranasal insulin and memory in early Alzheimer\u2019s disease. ClinicalTrialsgov. http:\/\/clinicaltrials.gov . http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clcentral\/articles\/747\/CN-00724747\/frame.html . Accessed 25 May 2017"},{"issue":"3","key":"8768_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3233\/JAD-141791","volume":"44","author":"A Claxton","year":"2015","unstructured":"Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A et al (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia. JAD 44(3):897\u2013906","journal-title":"JAD"},{"issue":"1","key":"8768_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A et al (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1):29\u201338","journal-title":"Arch Neurol"},{"issue":"3","key":"8768_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","volume":"27","author":"MA Reger","year":"2006","unstructured":"Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML et al (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27(3):451\u2013458","journal-title":"Neurobiol Aging"},{"issue":"3","key":"8768_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-2008-13309","volume":"13","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA et al (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. JAD 13(3):323\u2013331","journal-title":"JAD"},{"issue":"6","key":"8768_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","volume":"70","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B et al (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70(6):440\u2013448","journal-title":"Neurology"},{"issue":"12","key":"8768_CR35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s40263-014-0214-y","volume":"28","author":"MH Rosenbloom","year":"2014","unstructured":"Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP et al (2014) A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer\u2019s disease. CNS Drugs 28(12):1185\u20131189","journal-title":"CNS Drugs"},{"issue":"4","key":"8768_CR36","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3233\/JAD-161256","volume":"57","author":"S Craft","year":"2017","unstructured":"Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH et al (2017) Effects of regular and long-acting insulin on cognition and Alzheimer\u2019s disease biomarkers: a pilot clinical trial. JAD 57(4):1325\u20131334","journal-title":"JAD"},{"issue":"6","key":"8768_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0306-4530(02)00087-2","volume":"28","author":"S Craft","year":"2003","unstructured":"Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K et al (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer\u2019s disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28(6):809\u2013822","journal-title":"Psychoneuroendocrinology"},{"key":"8768_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1749-6632.2000.tb06371.x","volume":"903","author":"S Craft","year":"2000","unstructured":"Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA et al (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer\u2019s disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 903:222\u2013228","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"8768_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000054469","volume":"70","author":"S Craft","year":"1999","unstructured":"Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J et al (1999) Insulin metabolism in Alzheimer\u2019s disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70(2):146\u2013152","journal-title":"Neuroendocrinology"},{"issue":"4","key":"8768_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"ME Risner","year":"2006","unstructured":"Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM et al (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics J 6(4):246\u2013254","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"8768_CR41","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/aje\/kwi092","volume":"161","author":"LJ Podewils","year":"2005","unstructured":"Podewils LJ, Guallar E, Kuller LH, Fried LP, Lopez OL, Carlson M et al (2005) Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 161(7):639\u2013651","journal-title":"Am J Epidemiol"},{"issue":"3","key":"8768_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0197-4580(03)00087-3","volume":"25","author":"MA Reger","year":"2004","unstructured":"Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS et al (2004) Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 25(3):311\u2013314","journal-title":"Neurobiol Aging"},{"issue":"6","key":"8768_CR43","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1073\/pnas.061509598","volume":"98","author":"EM Reiman","year":"2001","unstructured":"Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J (2001) Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer\u2019s disease. Proc Natl Acad Sci USA 98(6):3334\u20133339","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"8768_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1073\/pnas.2635903100","volume":"101","author":"EM Reiman","year":"2004","unstructured":"Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D et al (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer\u2019s dementia. Proc Natl Acad Sci USA 101(1):284\u2013289","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"8768_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JAD-2010-100129","volume":"22","author":"J Valla","year":"2010","unstructured":"Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE et al (2010) Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer\u2019s susceptibility gene. JAD 22(1):307\u2013313","journal-title":"JAD"},{"issue":"16","key":"8768_CR46","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16):1349\u20131356","journal-title":"JAMA"},{"issue":"11","key":"8768_CR47","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry 141(11):1356\u20131364","journal-title":"Am J Psychiatry"},{"issue":"10","key":"8768_CR48","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","volume":"29","author":"C Benedict","year":"2004","unstructured":"Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J et al (2004) Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29(10):1326\u20131334","journal-title":"Psychoneuroendocrinology"},{"key":"8768_CR49","doi-asserted-by":"crossref","unstructured":"Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL et al (2007) Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 32(1):[239\u201343\u00a0pp.]. http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clcentral\/articles\/869\/CN-00571869\/frame.html . Accessed 15 Nov 2017","DOI":"10.1038\/sj.npp.1301193"},{"issue":"6","key":"8768_CR50","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s11892-012-0318-z","volume":"12","author":"V Pandyarajan","year":"2012","unstructured":"Pandyarajan V, Weiss MA (2012) Design of non-standard insulin analogs for the treatment of diabetes mellitus. Curr DiabRep 12(6):697\u2013704","journal-title":"Curr DiabRep"},{"issue":"3","key":"8768_CR51","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.diabres.2008.05.007","volume":"81","author":"T Wada","year":"2008","unstructured":"Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T (2008) Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract 81(3):269\u2013277","journal-title":"Diabetes Res Clin Pract"},{"issue":"1\u20132","key":"8768_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2003.10.015","volume":"147","author":"CA Colton","year":"2004","unstructured":"Colton CA, Needham LK, Brown C, Cook D, Rasheed K, Burke JR et al (2004) APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol 147(1\u20132):62\u201367","journal-title":"J Neuroimmunol"},{"issue":"4","key":"8768_CR53","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2337\/db09-1493","volume":"59","author":"M Hallschmid","year":"2010","unstructured":"Hallschmid M, Jauch-Chara K, Korn O, Molle M, Rasch B, Born J et al (2010) Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes 59(4):1101\u20131107","journal-title":"Diabetes"},{"issue":"5","key":"8768_CR54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/dmrr.397","volume":"19","author":"A Kupila","year":"2003","unstructured":"Kupila A, Sipila J, Keskinen P, Simell T, Knip M, Pulkki K et al (2003) Intranasally administered insulin intended for prevention of type 1 diabetes\u2014a safety study in healthy adults. Diabetes\/Metabol Res Rev 19(5):415\u2013420","journal-title":"Diabetes\/Metabol Res Rev"},{"issue":"3","key":"8768_CR55","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2337\/dc13-1672","volume":"37","author":"V Novak","year":"2014","unstructured":"Novak V, Milberg W, Hao Y, Munshi M, Novak P, Galica A et al (2014) Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care 37(3):751\u2013759","journal-title":"Diabetes Care"},{"issue":"4","key":"8768_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0168-8227(87)80039-6","volume":"3","author":"AG Frauman","year":"1987","unstructured":"Frauman AG, Jerums G, Louis WJ (1987) Effects of intranasal insulin in non-obese type II diabetics. Diabetes Res Clin Pract 3(4):197\u2013202","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"8768_CR57","first-page":"372","volume":"27","author":"D Lalej-Bennis","year":"2001","unstructured":"Lalej-Bennis D, Boillot J, Bardin C, Zirinis P, Coste A, Escudier E et al (2001) Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance. Diabetes Metabol 27(3):372\u2013377","journal-title":"Diabetes Metabol"},{"issue":"5","key":"8768_CR58","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2337\/diacare.10.5.573","volume":"10","author":"AG Frauman","year":"1987","unstructured":"Frauman AG, Cooper ME, Parsons BJ, Jerums G, Louis WJ (1987) Long-term use of intranasal insulin in insulin-dependent diabetic patients. Diabetes Care 10(5):573\u2013578","journal-title":"Diabetes Care"},{"issue":"8","key":"8768_CR59","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1046\/j.1464-5491.2001.00528.x","volume":"18","author":"D Lalej-Bennis","year":"2001","unstructured":"Lalej-Bennis D, Boillot J, Bardin C, Zirinis P, Coste A, Escudier E et al (2001) Efficacy and tolerance of intranasal insulin administered during 4\u00a0months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross-over study. Diabetic Med 18(8):614\u2013618","journal-title":"Diabetic Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8768-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T03:38:52Z","timestamp":1570678732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8768-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["8768"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8768-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"8 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliances with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was not sponsored by any company. Dr. Avgerinos reports no disclosures. Dr. Kalaitzidis reports no disclosures. Dr. Malli reports no disclosures. Dr. Kalaitzoglou reports no disclosures. Dr. Myserlis reports no disclosures. Dr. Lioutas reports no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}